explore -WSS

explore

author：comprehensive 2025-09-30 16:24:53 - browse：5958

Beam Therapeutics said Thursday morning it would lay off 20% of its staff — or around 100 employees — and pause or reevaluate certain programs as it looks to cut costs.

It’s a notable setback for a gene-editing company that quickly raised over $1 billion in the few years after its co-founder, David Liu, described a new form of CRISPR, called base editing, that allowed researchers to change individual letters of DNA. The biotech hired rapidly, announced its intention to treat a broad range of diseases, and received clearance to start clinical trials in cancer and sickle cell.

Beam, however, has struggled to enroll patients in those trials. Meanwhile, the biotech stock market has stayed cold, including for gene-editing companies, whose technologies raise new regulatory, safety, and reimbursement questions. The pending approval of two gene therapies for sickle cell would also limit the market for Beam’s lead drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Humana CEO Bruce Broussard to step down in 2024

focus

WSS

Dario to buy mental health app maker Twill in cash and stock deal

How should state employee insurance handle Wegovy?

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

There’s no way to know how good AI health technologies are

New documents shed light on MD Anderson Cancer Institute feud

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

focus

explore

focus

Medical records are filled with copy

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

Alkermes shareholders re

Massive project maps cells in human brain in unprecedented detail

Malaria cases in Florida and Texas: Here’s what you need to know

Female surgeons have lower rates of long

BioMarin wins approval for gene therapy to treat hemophilia A

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

Affirmative action in medical school literally saved lives

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

entertainment

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Community Health Systems hospitals under DOJ investigation

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

In utero gene editing: an explainer

A fraught question for the kids of Alzheimer’s: Is it coming for us?

A new nitrogen execution bill also undermines medical licensing

hotspot

focus

knowledge

focus